Merck Reaffirms Commitment To Consumer Care In Restructuring
This article was originally published in The Rose Sheet
Merck says it remains committed to retaining consumer care and animal health, though it continues to evaluate the businesses. Competitors such as Pfizer and Bristol-Myers Squibb successfully spun out non-pharma assets following similar restructurings.
You may also be interested in...
Merck executives shift their position regarding the potential divestiture of non-pharma assets, including the firm’s consumer-health business. J.P. Morgan analysts expect a sale of the consumer unit, and say Merck’s brands, including Claritin and Coppertone, could grow globally with a new owner.
Germany’s Merck KGaA could join the ranks of firms like Pfizer potentially looking to leave the consumer health care product business, market analysts argue.
Pfizer's proposed $68 billion acquisition of Wyeth brings the return of a consumer health division and with it a pipeline structure for potential Rx-to-OTC switches